iThera Medical – Leading the Field of
Optoacoustic Imaging

Spun off in 2010 from one of the leading
optoacoustics institutes in the world

iThera Medical was founded in 2010 as a spin-off from the Institute of Biological and Medical Imaging (IBMI) at the Helmholtz Center Munich. Two leading optoacoustics researchers, Prof. Vasilis Ntziachristos (left) and Prof. Daniel Razansky (right), are co-founders of the company.

Prof. Vasilis Ntziachristos (left), Prof. Daniel Razansky (right)

Driving the field of optoacoustic imaging,
both for preclinical and clinical use

Since foundation in 2010, iThera Medical has pioneered the use of optoacoustics for biomedical imaging. Initially focusing on the field of preclinical research, in the last years the company has expanded its product portfolio and translated its technologies into the clinical arena, in close collaboration with its customers and technology partners.

Today, iThera Medical is the undisputed leader in the field of optoacoustic imaging, as defined by its global footprint of users, its comprehensive product portfolio, and the vast range of peer-reviewed publications covering preclinical and clinical applications.

Our mission: Establishing optoacousticimaging in the clinical routine

Going forward, iThera Medical intends to bring its technologies into routine clinical use. Various investigator-initiated clinical trials have been successfully completed – in areas as promising and diverse as inflammatory bowel disease, breast cancer, systemic sclerosis, arteriovenous malformations, and muscular dystrophy. The next step will be the regulatory approval (CE and FDA) of the MSOT Acuity as a medical device and multi-center trials to validate the clinical utility. To achieve this, iThera Medical has assembled a world-class team, including scientists with a background in the areas of engineering, physics, biology, and medicine. iThera Medical is constantly expanding its team of professionals. If you are interested in being a part of this “imaging revolution,” please see Careers.

Subscribe to our Newsletter
News & more